Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Whitney Montgomery

Physician Assistant Shenandoah, TX Physician Assistant

NPI 1306155601 CMS profile 13845

9200 Pinecroft Dr, Suite 130, Shenandoah, TX 77380

Open in the dashboard

General payments

$13,258

617 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Whitney Montgomery of Shenandoah, TX is reported in the CMS Open Payments database as having received $13,258 across 617 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,234 145
2024 General $2,821 123
2023 General $2,389 111
2022 General $2,659 129
2021 General $2,156 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Whitney Montgomery
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Whitney Montgomery were reported at $3,234. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Whitney Montgomery Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,156 $132 $37–$438 $132
2022 $2,659 $155 $48–$522 $149
2023 $2,389 $167 $52–$557 $160
2024 $2,821 $178 $55–$600 $164
2025 $3,234 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,724 90 payments
  2. UCB, Inc. $1,255 46 payments
  3. Medtronic, Inc. $909 17 payments
  4. Eisai Inc. $834 43 payments
  5. AstraZeneca Pharmaceuticals LP $695 23 payments
  6. Novartis Pharmaceuticals Corporation $679 52 payments
  7. Pfizer Inc. $666 28 payments
  8. Neurocrine Biosciences, Inc. $540 32 payments
  9. Biohaven Pharmaceutical Holding Company Ltd. $531 32 payments
  10. EMD Serono, Inc. $470 23 payments
  11. Other $4,953 231 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,098 615 payments
  2. Education $160 2 payments
Products named General payments · program years 2021–2025
  1. QULIPTA $740 44 payments
  2. NURTEC ODT Primary Care $726 43 payments
  3. NURTEC ODT Pain $666 28 payments
  4. ACTIVA PC $648 14 payments
  5. ANDEXXA $626 19 payments
  6. BOTOX $622 31 payments
  7. ZAVZPRET $574 21 payments
  8. Briviact $554 18 payments
  9. KESIMPTA $503 42 payments
  10. UBRELVY $463 38 payments
  11. Other $7,871 378 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,904

Median for Physician Assistant: 241

Drug cost

$366,433

Median for Physician Assistant: $4,110

Branded share of claims

34.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 12 $90,412
Nurtec Odt Rimegepant Sulfate Brand 49 $78,026
Rufinamide Generic 12 $32,230
Ongentys Opicapone Brand 34 $31,602
Rexulti Brexpiprazole Brand 13 $24,646
Qulipta Atogepant Brand 18 $21,489
Aimovig Autoinjector Erenumab-Aooe Brand 26 $19,103
Emgality Pen Galcanezumab-Gnlm Brand 20 $14,019
Memantine Hcl Er Memantine Hcl Brand 94 $8,760
Memantine Hcl Generic 198 $7,167

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$30,518

Medicare's payments for the services billed

Medicare patients

262

Average age 75

Services billed

415

163 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 41%
Depression 34%
Alzheimer's or dementia 30%
Diabetes 29%
Chronic kidney disease 26%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Rystiggo
  • UCB, Inc. $275
$275 — —
QULIPTA
  • AbbVie, Inc. $211
$211 18 —
BOTOX
  • AbbVie, Inc. $174
$174 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $163
$163 — —
Sunosi
  • Axsome Therapeutics, Inc. $147
$147 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

617 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record